| Diffuse Large B-Cell Lymphoma
Polivy vs Columvi
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Polivy vs Columvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsColumvi has a higher rate of injection site reactions vs Polivy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Columvi but not Polivy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Polivy
Columvi
At A Glance
IV infusion
Every 21 days
CD79b-directed antibody-drug conjugate
IV infusion
Every 3 weeks
CD20xCD3 bispecific T-cell engager
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma (previously untreated), HGBL 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP); administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with bendamustine and a rituximab product; administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, constipation, alopecia, mucositis, pyrexia, decreased appetite
Serious Peripheral neuropathy, infusion-related reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy, tumor lysis syndrome, hepatotoxicity, infusion site extravasation injury
Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue
Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare
Pharmacology
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate; the monoclonal antibody binds CD79b on B cells, is internalized, and releases MMAE intracellularly via lysosomal protease cleavage, where MMAE binds microtubules to inhibit cell division and induce apoptosis in dividing B cells.
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Polivy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Columvi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Polivy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Columvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Polivy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Columvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Genentech Patient FoundationCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PolivyView full Polivy profile
ColumviView full Columvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.